Trial abstract · §3

MARITIDE-PH2-OBESITY — results

Primary endpoint, absolute and relative effect where derivable, and harms as reported.

Document identifier: CEI-TR-0147/3
Series: Trial abstract
Version: 1.3
Published: 12 Feb 2024
Last reviewed: 12 Jan 2025
Next review: 12 Jan 2027
Identifier: 10.71829/cei.trial.147
Certainty: Low
Cycle: 2024 Q1
Phase: Phase 2
Status: Reported

§3Results

§3.1Primary endpoint

Table 3. Primary endpoint as reported.

Endpoint	Result as reported	Certainty
Percentage change in body weight from baseline to week 52	Mean change of approximately −20 % at the highest dose without a weight plateau at 52 weeks	Low
Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed.

§3.2Endpoint hierarchy

Figure 1. Illustrative. Categorical responder proportions derived by the Institute from the reported mean change under a logistic response model. These are not the published responder proportions for this trial. The figure is published because a mean conceals the distribution of response, and the shape of that distribution is what a reader most often wants and least often gets.

§3.3Harms as reported

Table 5. Adverse events for Maridebart cafraglutide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.

Event	Active, %	Comparator, %	Source trial
Nausea	—	—	High incidence on first dose, attributed to the loading regimen; substantially lower on subsequent doses
Vomiting	—	—	Reported at high incidence on initiation
Injection-site reaction	—	—	Reported
Discontinuation for adverse events	—	—	Concentrated in the first dosing interval

Compound Evidence Institute · CEI-TR-0147/3 · https://compoundevidence.com/trials/maritide-ph2-obesity/results/ · retrieved 30 July 2026